Spondyloarthritis is a class of chronic autoimmune inflammatory diseases that share common genetic and clinical features. Axial spondyloarthritis is one of these diseases that predominantly affects the axial skeleton, especially the spine and sacroiliac joints. Some of the major symptoms of axial spondyloarthritis could be dealt with the use of non-steroidal anti-inflammatory drugs (NSAIDs). These drugs could carry disease-modifying properties such as delaying the structural damage of the spine. Apart from NSAIDs, tumor necrosis factor (TNF) α blockers are approved and considered effective to treat active axial spondyloarthritis. Besides these, there are a number of new drugs currently under investigation.
The research study covers top players of the global axial spondyloarthritis treatment market such as UCB Biosciences GmbH, Pfizer, Abbott Pharmaceuticals, Merck Sharp & Dohme Corp., and GlaxoSmithKline plc. Each player is carefully assessed in the report with key focus on their market share, recent developments, production, revenue, and other vital factors.
Drug manufacturers are launching new products in the global axial spondyloarthritis treatment market to gain growth and strengthen their customer base. In April 2019, Eli Lilly and Company, a US-based global pharmaceutical company, announced that its monoclonal antibody Taltz (ixekizumab) has cleared the phase 3 study COAST-X. This study evaluated Taltz’s efficacy and safety when used to treat non-radiographic axial spondyloarthritis.
Get PDF template of this report: https://www.qyrconsulting.com/request-sample/7247
The demand for axial spondyloarthritis treatment is anticipated to increase as there are a large number of patients with the disease across the world. As mentioned on the Johns Hopkins Arthritis Center’s website, approximately 0.2-0.5% of the US population is affected by ankylosing spondylitis. While non-radiographic axial spondyloarthritis is more common in females, ankylosing spondylitis occurs more frequently in male adults. Axial spondyloarthritis could usually include a series of extra-articular manifestations and co-morbidities, which includes uveitis, inflammatory bowel disease, and cardiovascular risk.
With the increase in the incidence of axial spondyloarthritis, there has been a rise in the number of approved biosimilar drugs. This is predicted to push the growth of the global axial spondyloarthritis treatment market. However, the expensive cost of biologics is foretold to delay the rise of the global market. Biologics could be expensive due to the requirement of high research and development investment and time-consuming manufacturing and testing procedures.
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
Among type segments, ankylosing spondylitis is expected to show significant growth in the global axial spondyloarthritis treatment market. It is a type of arthritis where the inflammation of spinal joints is involved, which could cause chronic or severe discomfort and pain. Although it mainly affects the spine, other joints could also be affected because of the disease.
According to analysts, North America is prognosticated to achieve a remarkable share of the global axial spondyloarthritis treatment market due to favorable reimbursement scenarios, higher amount of income spent on healthcare compared to other regions, and increased awareness about the disease. Asia Pacific is foreseen to show quicker growth in the global market because of the improvement in healthcare infrastructure, large population, and increase in the number of geriatrics.
Report TOC, Figures and Tables: https://www.qyrconsulting.com/reports/global-axial-spondyloarthritis-treatment-market
Table of Contents
Overview of the Report: The report starts with research scope, major players studied by the authors, years considered for the research study, objectives of the study, and analysis of market share by application and market size growth rate by type.
Global Growth Trends: Here, the size of the global Bio-pharma market is studied along with sales and revenue analysis. This section also includes industry trends and analysis of the growth rate of the global Bio-pharma market by region.
Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of revenue, sales, and share in the global Bio-pharma market.
Company Profiles: Almost all leading companies operating in the global Bio-pharma market are profiled in this section, taking into account their recent developments, market share, and other vital factors.
Market Forecast: Apart from revenue and sales forecast of the global Bio-pharma market, this section provides forecast of all
We established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.